-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 25th, Pioneer Pharmaceuticals announced that it has reached a cooperation agreement with Indonesian biotech company Etana Biotechnologies (Etana) on the commercialization of prokulamide in the treatment of COVID-19 in Indonesia (hereinafter referred to as "Indonesia")
.
According to the agreement, Kaifeng Pharmaceutical will receive a down payment and milestone payment from Etana.
In addition, it will also receive economic benefits related to the sale of prokruamide in Indonesia.
The transaction is in line with industry practices
.
Prokalamide is a new generation of androgen receptor antagonist independently developed by Kaixing Pharmaceutical.
Since the pandemic of the new crown epidemic in early 2020, Kaixing Pharmaceutical has rapidly started research on the use of procluamide for the treatment of new crowns
.
At present, procrulamide is undergoing three global multi-center phase III clinical trials of new crown treatment in the United States, South America (including Brazil), the European Union, Asia and other countries and regions, and was granted the first emergency use authorization by Paraguay in July 2021 (EUA)